FDA Approves Foundayo, New GLP-1 Weight Loss Pill Without Food, Water or Timing Restrictions

People who take this pill don't have to adhere to rules like taking it first thing in the morning or on an empty stomach.

What exactly are GLP-1 medications and how do they work?

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...
The Lancet

Are India and China ready for a “chaotic surge” of generic obesity drugs?

As patents on semaglutide expire, manufacturers are poised to introduce cheaper generic versions of blockbuster drugs, with far-reaching effects on the obesity crisis. Megan Tatum reports.
MPR

GLP-1 Receptor Agonists May Lower Risk for Worsening Mental Illness

HealthDay News — Glucagon-like peptide-1 (GLP-1) receptor agonists, especially semaglutide, are associated with a reduced risk for worsening of anxiety and depression that co-occur with diabetes and ...

GLP-1 Receptor Agonist Market to Hit USD 78.4 Billion by 2032, Growing at a CAGR of 3.66% with Rising Demand for Metabolic Disease Therapies | MarkNtel Advisors

According to the in-depth study published by MarkNtel Advisors, the Global GLP-1 Receptor Agonist Market is projected to grow at a CAGR of around 3.66% during 2026–2032. The market expansion is ...
Medical Dialogues

FDA Approves Orforglipron as Second Oral GLP-1 Agonist for Weight Loss

The FDA has approved Orforglipron as the second oral GLP-1 receptor agonist for weight management in adults with obesity or ...
Science Daily

Genetic evidence that diabetes drug GLP-1 receptor agonists achieve weight loss primarily by reducing fat mass more than muscle

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
Medscape

Drug-Drug Interactions With Glucagon-like Peptide-1 Receptor Agonists

The Annals of Pharmacotherapy. 2012;46(5):710-717. There are several limitations to the available data. First, single-dose drug interaction studies do not permit examination of the effects of repeat ...